Associated Papers
Pathogenic variants of sphingomyelin synthase SMS2 disrupt lipid landscapes in the secretory pathway.
Sokoya T et al.
Elife, 2022
Osteoporosis and skeletal dysplasia caused by pathogenic variants in SGMS2.
Pekkinen M et al.
Jci Insight, 2019
Discovery and characterization of selective human sphingomyelin synthase 2 inhibitors.
Adachi R et al.
European Journal of Medicinal Chemistry, 2017
Select a paper to view details